“By combining information about many patients from a collection of studies, our analysis determined that the more aggressive combination chemotherapy does not benefit older colon cancer patients as it does for those who are younger,” says Nadine Jackson McCleary, M.D., Ph.D., Dana-Farber gastrointestinal oncologist and the study’s lead author. Dr. Jackson McCleary received a 2008–2009 ASCO Young Investigator’s Award.
Adding oxaliplatin to chemotherapy treatment with 5FU reduces the risk of recurrence among patients less than 70 years old who have had their primary cancer removed, the study determined. This finding was expected, based on the results of previous individual trials. Patients under 70 who were treated with 5FU and oxaliplatin had improved disease-free survival, with the addition of oxaliplatin relatively reducing the risk of recurrence or death by approximately 15 percent. Patients 70 and older who were treated with the combined drug therapy, however, did not have improved outcomes, compared to patients who received 5FU alone.
“We found that adding chemotherapy agents to the standard 5FU regimen in older patients after surgery did not provide the benefits that younger patients see,” says Dan Sargent, Ph.D., of Mayo Clinic, a collaborator on the study. “For the older patient, this means that it is appropriate to choose the better tolerated treatment strategy of 5FU alone.”
The benefit of postsurgical treatment for both young and older colon cancer patients with 5FU was documented in a study authored by Dr. Sargent and colleagues in the New England Journal of Medicine in 2001. By 2003, however, oxaliplatin was approved for use in combination with 5FU, because the combination boosted the impact of 5FU on extending disease-free survival after colon cancer surgery. While the combined treatment carried additional risk of side effects, physicians prescribed the treatment strategy to patients of all ages. Initially, studies that examined age-related impact of the aggressive combination of chemotherapies did not indicate a difference in survival or recurrence related to patient age.
The current study being presented at the ASCO annual meeting includes a large enough patient base to powerfully discern differences related to age that are due to treatment regime.
“The younger patients do get an additional boost from both drugs used together,” Dr. Jackson McCleary notes. “Older patients don’t benefit from that combination of treatment.”
The findings arise from analysis of combined data collected within an expanded database by the Adjuvant Colon Cancer End Points (ACCENT) Group, a consortium of scientists. The ACCENT database includes data from more than 33,500 patients from the United States, Canada, Australia and Europe. ACCENT, chaired by Dr. Sargent, is supported by the North Central Cancer Treatment Group (NCCTG).
“At this point we can only speculate as to why older patients do not benefit from combined chemotherapies,” says Jeffrey Meyerhardt, M.D., M.P.H., of Dana-Farber and co-investigator on the trial. “We do know that a higher number of older patients have to stop the drug before completing the full six-month prescribed course of treatment.”
“These studies add to the knowledge base that defines how to choose treatment strategies for every individual patient,” Dr. Sargent says. “Age may become as important a consideration as tumor-specific factors when defining individual medical options for colorectal cancer patients.”
Approximately half of all colon cancer patients are older than 70. While about half of the colon cancer patients over 70 will live for five years, those with recurrence typically develop additional tumors within three years. The disease is diagnosed in a million people worldwide every year. In the United States, colorectal cancer accounts for 10 percent of new cancer cases, as well as 10 percent of cancer-related deaths every year.
Drs. Jackson McCleary, Meyerhardt, and Sargent conducted the analysis on the expanded database in concert with an international team of scientist participating in ACCENT, including Erin Green of Mayo Clinic; Greg Yothers, Ph.D., Biostatistical Center and University of Pittsburgh; Aimery de Gramont, M.D., Hôpital Saint-Antoine in Paris, France; Eric Van Cutsem, M.D., Ph.D., University of Leuven and Gasthuisberg University Hospital, Leuven, Belgium; Michael O’Connell, M.D., Mayo Clinic; Christopher Twelves, M.D., Cancer Research UK Clinical Centre, Leeds, United Kingdom; and Leonard Saltz, M.D., Weill Medical College of Cornell University and Sloan-Kettering Cancer Center.
ORLANDO — The combination of chemotherapies 5FU and oxaliplatin, compared to 5FU alone, decreases colon cancer recurrence after surgery and promotes longer survival for patients under 70 — but not for those who are older, according to Mayo Clinic and Dana-Farber Cancer Institute scientists. They will present the study's findings Saturday, May 30, at the American Society of Clinical Oncology annual meeting in Orlando.
Share this Article
Related Content In Gastrointestinal Oncology
Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma
Oncology & Hematology Review. 2020;16(2):90–4 DOI: https://doi.org/10.17925/OHR.2021.16.2.90
Esophageal cancer is the seventh most common malignancy and the sixth leading cause of death from cancer worldwide.1 The main histological subtypes are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma. ESCC is the most common subtype, and the frequency of this disease is highest in Eastern Asia and Eastern Africa.2 In Western countries, however, the incidence […]
FOREWORD – EUROPEAN ONCOLOGY & HAEMATOLOGY – VOLUME 16 ISSUE 1 – SUMMER 2020
European Oncology & Haematology. 2020;16(1):11
Welcome to the summer edition of European Oncology & Haematology. The COVID-19 pandemic has had a devastating impact on cancer and other illness care. In addition to the heightened susceptibility of patients with cancer to infections, lockdown has resulted in delayed screening and reduced treatment of early-stage disease. However, things are starting to move in the […]
Improving Outcomes in Pancreatic Cancer
Oncology & Haematology Review (US). 2020;16(1):59–66 DOI: https://doi.org/10.17925/OHR.2020.16.1.59
Pancreatic ductal adenocarcinoma (PDA) is predicted to beat colon cancer in terms of total cancer-related deaths in the USA by this year (2020).1 Given this projected burden of disease, efforts in understanding and developing new treatments for PDA are paramount. In this review, we will summarize the molecular characteristics and mutations thought to be involved with […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!